Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment
Authors:
- 22 April 2021
- journal article
- case report
- Published by S. Karger AG in Acta Haematologica
- Vol. 144 (6) , 683-687
Abstract
Pure red cell aplasia (PRCA) can potentially occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT) if recipient and donor ABO blood groups are mismatched, with the recipient having isoagglutinins against the donor blood group. Patient plasma cells that survive transplant conditioning produce anti-ABO isoagglutinins targeting donor erythroid precursors in the bone marrow and thus causing red cell aplasia. Therapeutic options include steroids, discontinuation of immunosuppression, plasmapheresis, donor lymphocyte infusion, rituximab, and bortezomib, all with limited benefit. Daratumumab utilized in the treatment of multiple myeloma is an anti-CD38 monoclonal antibody targeting plasma cells, which makes it a potentially efficient therapy for PRCA. The current case report presents a patient with post-allo-HSCT PRCA cured with daratumumab applied after failure of other therapies. Our findings demonstrate safety and high efficiency of daratumumab, suggesting its applicability as early treatment of post-allo-HSCT PRCA.Keywords
This publication has 12 references indexed in Scilit:
- Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumabEuropean Journal of Haematology, 2019
- Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumabAmerican Journal of Hematology, 2019
- Daratumumab for Delayed Red-Cell Engraftment after Allogeneic TransplantationNew England Journal of Medicine, 2018
- Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2018
- Successful high-dose dexamethasone treatment of acquired pure red cell aplasia following ABO major mismatched allogeneic hematopoietic stem cell transplantation.2016
- Efficacy of plasmapheresis for the treatment of pure red blood cell aplasia after allogeneic stem cell transplantationTransfusion, 2015
- Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO‐incompatible haematopoietic stem cell transplantationTransfusion Medicine, 2014
- Outcomes after major or bidirectional ABO‐mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor‐type secretor plasma with or without plasma exchangeTransfusion, 2011
- Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusionEuropean Journal of Haematology, 2004
- Regeneration of erythropoiesis after related‐ and unrelated‐donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problemsTransfusion, 2000